A detailed history of Invesco Ltd. transactions in Novo Cure LTD stock. As of the latest transaction made, Invesco Ltd. holds 109,776 shares of NVCR stock, worth $3.38 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
109,776
Previous 109,892 0.11%
Holding current value
$3.38 Million
Previous $1.88 Million 8.87%
% of portfolio
0.0%
Previous 0.0%

Shares

24 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$15.61 - $23.34 $1,810 - $2,707
-116 Reduced 0.11%
109,776 $1.72 Million
Q2 2024

Aug 13, 2024

SELL
$11.83 - $24.05 $369,616 - $751,418
-31,244 Reduced 22.14%
109,892 $1.88 Million
Q1 2024

May 14, 2024

BUY
$12.42 - $17.29 $447,318 - $622,716
36,016 Added 34.26%
141,136 $2.21 Million
Q4 2023

Feb 12, 2024

SELL
$11.13 - $15.78 $894,774 - $1.27 Million
-80,393 Reduced 43.34%
105,120 $1.57 Million
Q3 2023

Nov 13, 2023

BUY
$16.15 - $42.35 $491,541 - $1.29 Million
30,436 Added 19.63%
185,513 $3 Million
Q2 2023

Aug 11, 2023

BUY
$40.29 - $82.51 $133,964 - $274,345
3,325 Added 2.19%
155,077 $6.44 Million
Q1 2023

May 12, 2023

BUY
$56.44 - $118.81 $86,409 - $181,898
1,531 Added 1.02%
151,752 $9.13 Million
Q4 2022

Feb 13, 2023

BUY
$63.98 - $85.37 $4.36 Million - $5.81 Million
68,087 Added 82.9%
150,221 $11 Million
Q3 2022

Nov 14, 2022

SELL
$67.99 - $89.57 $280,186 - $369,117
-4,121 Reduced 4.78%
82,134 $6.24 Million
Q2 2022

Aug 15, 2022

BUY
$56.6 - $89.9 $901,468 - $1.43 Million
15,927 Added 22.65%
86,255 $5.99 Million
Q1 2022

May 16, 2022

BUY
$60.15 - $84.52 $600,657 - $844,016
9,986 Added 16.55%
70,328 $5.83 Million
Q4 2021

Feb 14, 2022

SELL
$75.08 - $121.99 $6.54 Million - $10.6 Million
-87,160 Reduced 59.09%
60,342 $4.53 Million
Q3 2021

Nov 15, 2021

SELL
$116.17 - $194.55 $11.3 Million - $18.9 Million
-97,242 Reduced 39.73%
147,502 $17.1 Million
Q2 2021

Aug 17, 2021

BUY
$130.4 - $225.58 $15.6 Million - $27 Million
119,829 Added 95.93%
244,744 $54.3 Million
Q1 2021

May 17, 2021

BUY
$124.11 - $190.17 $7.35 Million - $11.3 Million
59,185 Added 90.04%
124,915 $16.5 Million
Q4 2020

Feb 16, 2021

BUY
$112.16 - $174.14 $5.54 Million - $8.6 Million
49,380 Added 302.02%
65,730 $11.4 Million
Q3 2020

Nov 16, 2020

SELL
$58.05 - $111.31 $628,623 - $1.21 Million
-10,829 Reduced 39.84%
16,350 $1.82 Million
Q2 2020

Aug 14, 2020

SELL
$57.2 - $74.41 $38 Million - $49.4 Million
-663,478 Reduced 96.06%
27,179 $1.61 Million
Q1 2020

May 15, 2020

SELL
$57.05 - $95.75 $15.4 Million - $25.9 Million
-270,565 Reduced 28.15%
690,657 $46.5 Million
Q4 2019

Feb 14, 2020

BUY
$68.3 - $93.8 $27.2 Million - $37.3 Million
397,564 Added 70.53%
961,222 $81 Million
Q3 2019

Nov 14, 2019

SELL
$61.86 - $97.8 $2.21 Million - $3.5 Million
-35,779 Reduced 5.97%
563,658 $42.2 Million
Q2 2019

Aug 14, 2019

BUY
$42.22 - $63.23 $9.43 Million - $14.1 Million
223,352 Added 59.39%
599,437 $37.9 Million
Q1 2019

May 15, 2019

BUY
$31.96 - $56.12 $5.3 Million - $9.31 Million
165,815 Added 78.86%
376,085 $18.1 Million
Q4 2018

Feb 14, 2019

BUY
$28.72 - $52.63 $6.04 Million - $11.1 Million
210,270 New
210,270 $7.04 Million

Others Institutions Holding NVCR

About NovoCure Ltd


  • Ticker NVCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Instruments & Supplies
  • Shares Outstandng 104,950,000
  • Market Cap $3.23B
  • Description
  • NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...
More about NVCR
Track This Portfolio

Track Invesco Ltd. Portfolio

Follow Invesco Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Invesco Ltd. with notifications on news.